Af­ter care­ful­ly build­ing up ex­pec­ta­tions, a small-cap biotech’s big plans come crash­ing down in PhI­II cat­a­stro­phe

Cor­bus Phar­ma­ceu­ti­cals spent years build­ing up in­vestors’ hopes in lenaba­sum. It took sec­onds to punc­ture those ex­pec­ta­tions and de­stroy the stock $CRBP price.

Ear­ly Tues­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER